Literature DB >> 20714877

Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.

Changyu Wang1, Yanjie Weng, Hongyan Wang, Ying Shi, Ding Ma.   

Abstract

The mRNA and protein expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) and their relationship with prognosis were investigated. Real-time quantitative RT-PCR (Taqman) was used to detect the mRNA expression of TS, TP and DPD in formalin-fixed and paraffin-embedded 106 samples of epithelial ovarian cancer and 29 normal ovaries. A TATA box-binding protein (TBP) was used as an endogenous reference gene. A relationship between TS, TP, DPD expression and clinicopathologic features was investigated. The protein location and expression of TS, TP and DPD was examined in the same patients by an avidin-biotin-peroxidase immunohistochemistry. TS and TP mRNA expression levels were significantly higher in tumor group than in normal controls, with the average value of TS and TP mRNA being 6.14+/-0.62 and 0.59+/-0.06 in tumor tissue, and 0.71+/-0.14 and 0.16+/-0.04 in normal tissue, respectively. DPD mRNA expression levels were significantly lower in tumor group (0.11+/-0.02) than in normal controls (0.38+/-0.05). There was statistically significant difference in TS and TP mRNA expression levels among different pathological grades and clinical stages (P<0.05), but histological subtype was not significantly associated with TS and TP mRNA expression. DPD gene expression was not significantly associated with any clinicopathological parameters. Immunohistochemistry revealed that TP protein was mainly distributed in nucleus, and TS and DPD mainly in cytoplasm. The protein expression intensity of TS, TP and DPD was coincided with the mRNA expression levels. It was concluded that TS, TP mRNA and protein expression levels were significantly higher in epithelial ovarian cancer, and DPD mRNA and protein expression levels were significantly lower. The expression levels of TS and DPD were related to the patients' prognosis and survival. Combined gene expression levels of TS, TP and DPD represent a new variable to predict the clinical outcome in ovarian cancer. The association of TS, TP and DPD expression levels with survival suggests an importance of these genes for tumor occurrence and progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714877     DOI: 10.1007/s11596-010-0456-y

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  26 in total

1.  Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation.

Authors:  E S CANELLAKIS
Journal:  J Biol Chem       Date:  1956-07       Impact factor: 5.157

2.  beta-amino acid formation by tissue slices incubated with pyrimidines.

Authors:  R M FINK; K FINK; R B HENDERSON
Journal:  J Biol Chem       Date:  1953-03       Impact factor: 5.157

Review 3.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

4.  Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents.

Authors:  Hei-Cheul Jeung; Xiao-Fang Che; Misako Haraguchi; Tatsuhiko Furukawa; Chun-Lei Zheng; Tomoyuki Sumizawa; Sun-Young Rha; Jae Kyung Roh; Shin-ichi Akiyama
Journal:  Biochem Pharmacol       Date:  2005-07-01       Impact factor: 5.858

5.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

6.  Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

Authors:  Carmen J Allegra; Allyson L Parr; Lester E Wold; Michelle R Mahoney; Daniel J Sargent; Patrick Johnston; Pam Klein; Katie Behan; Michael J O'Connell; Ralph Levitt; John W Kugler; Maria Tria Tirona; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

7.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

Authors:  Anders Jakobsen; Jens Nederby Nielsen; Niels Gyldenkerne; Jan Lindeberg
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

8.  Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

Authors:  Miriam Koopman; Sabine Venderbosch; Harm van Tinteren; Marjolijn J Ligtenberg; Iris Nagtegaal; Johan H Van Krieken; Cornelis J Punt
Journal:  Eur J Cancer       Date:  2009-05-18       Impact factor: 9.162

Review 9.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

10.  Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.

Authors:  K Hata; T Kamikawa; S Arao; H Tashiro; H Katabuchi; H Okamura; R Fujiwaki; K Miyazaki; M Fukumoto
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  1 in total

1.  Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Authors:  Kenzo Iizuka; Cheng Jin; Kokoro Eshima; Mei Hua Hong; Kiyoshi Eshima; Masakazu Fukushima
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.